Combination therapy with lisuride and L-dopa in the early stages of Parkinson's disease decreases and delays the development of motoric fluctuations. Long-term study over 10 years in comparison with L-dopa monotherapy;Kombinationstherapie mit lisurid und L-dopa in den fruhstadien der Parkinson-krankheit verringert und verzogert die entwicklung motorischer fluktuationen. Langzeitstudie uber 10 jahre im vergleich mit einer L-dopa- monotherapie

Nervenarzt

Volumn 70, Issue SUPPL. 1, 1999, Pages

  Rinne, U K ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Dopamine agonist; Lisuride; Long term treatment; Motor fluctuations; Parkinson's disease

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; LISURIDE;

CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG INDUCED DISEASE; DYSKINESIA; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; PARKINSON DISEASE; PSYCHOSIS; REVIEW; TREATMENT OUTCOME;

EID: 0032942986     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001150050585     Document Type: Review

References (24)

1. Bédard PJ, Gomez Mancilla B, Blanchette P, Gagnon C, Di Paolo T (1992) Levodopa-induced dyskinesia: facts and fancy. What does the MPTP monkey model tell us? Can J Neurol Sci 19:134-137
2. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN (1994) Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 36:27-31
3. Caraceni T, Scigliano G, Musicco M (1991) The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression. Neurology 41:380-384
4. Duvoisin RC (1971) The evaluation of extrapyramidal disease. In:de Ajuriaguerra J, Gauthier G (eds) Monoamines, noyaux gris centraux et syndrome de Parkinson. Geneva:Georg et Cie SA 313-325
5. Giménez-Roldán S, Tolosa E, Burguera JA, Chacón J, Liaño H, Forcadell F (1997) Early combination of Bromocriptine and Levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind-stage. Clinical Neuropharmacology 20:67-76
6. Hely MA, Morris JGL, Reid WGJ, O'Sullivan DJ, Williamson PM, Rail D, Broe GA, Margrie S (1994) The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 57:903-910
7. Horstink MWIM, Zjilmans JCM, Pasman JW, Berger HJC, Korten JJ, van't Hof MA (1990) Which risk factors predict the levodopa response in fluctuating Parkinson's disease? Ann Neurol 27:537-543
8. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett, ES, Nahmias C, Jones T, Marsden CD (1986) Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neural Transm 49:853-860
9. Lieberman AN (1992) Dopamine agonists used as monotherapy in de novo PD patients: Comparisons with selegiline. Neurology 42 [Suppl 4]:37-40
10. Montastruc LJ, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 57:1034-1038
11. Parkinson's Disease Research Group in the United Kingdom (1993) Comparisons of therapeutic effects of levodopa, levodopa and selegine, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 307:469-472
12. Przuntek H, Welzel D, Blümner E, Danielczyk W, Letzel H, Kaiser H-J, Kraus PH, Riederer P, Schwarzmann D, Wolf H, Überla K (1992) Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol 43:357-363
13. Rinne UK (1981) Treatment of Parkinson's disease: problems with a progressing disease. J Neural Transm 51:161-174
14. Rinne UK (1983) Problems associated with long-term levodopa treatment of Parkinson's disease. Acta Neurol Scand 68 [Suppl 95]:19-26
15. Rinne UK (1985) Combined bromocriptine-levodopa therapy early in Parkinson's disease. Neurology 35:1196-1198
16. Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 37:826-828
17. Rinne UK (1989) Lisuride, a dopamine agonist, in the treatment of early Parkinson's disease. Neurology 39:336-339
18. Rinne UK, Sonninen V, Siirtola T (1976) Long-term treatment of parkinsonism with L-dopa and decarboxylase inhibitor: a clinical and biochemical approach. In: Birkmayer W, Hornykiewkz O (eds) Advances in parkinsonism. Editiones Roche, Basel, pp 555-565
19. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD, Dubini A, Orlando N, Grimaldi R and the PKDS009 Collaborative Study Group (1997) Cabergoline in the treatment of early Parkinson's disease. Results of the first year of treatment in a couple blind comparison between cabergoline and levodopa. Neurology 48:363-388
20. Rinne UK, Bracco F, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL, Marsden CD and the PKDS009 Study Group (1998) Early treatment of Parkinson's disease with Cabergoline delays the onset of motor complications. Results of the double-blind Levodopa controlled trial. Drugs 55 [Suppl 1]:23-30
21. Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA (1994) Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry 57:562-566
22. Weiner WJ, Factor SA, Sanchez-Ramos JR, et al (1993) Early combination therapy (bromocriptine and levodopa) does not prevent motor fluctuations in Parkinson's disease. Neurology 43:21-27
23. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA (1995) Dopamine agonist in Parkinson's disease. Neurology 45 [Suppl 3]:S28-S34
24. Yahr MD (1976) Evalution of long-term therapy in Parkinson's disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O (eds) Advances in parkinsonism. Editiones Roche, Basel, pp 435-443